NewAmsterdam Pharma (NASDAQ:NAMS) Trading 5.6% Higher

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) were up 5.6% on Monday . The company traded as high as $20.30 and last traded at $20.28. Approximately 26,266 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 206,641 shares. The stock had previously closed at $19.21.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, June 7th. Scotiabank started coverage on NewAmsterdam Pharma in a report on Thursday, March 14th. They issued a “sector outperform” rating and a $35.00 price target for the company. Finally, TD Cowen initiated coverage on NewAmsterdam Pharma in a report on Wednesday, May 15th. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Buy” and an average target price of $33.25.

NewAmsterdam Pharma Trading Up 3.9 %

The business has a fifty day moving average price of $19.94 and a 200 day moving average price of $19.31.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.08). The firm had revenue of $1.40 million for the quarter, compared to analyst estimates of $2.95 million. Research analysts predict that NewAmsterdam Pharma will post -2.52 earnings per share for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CEO Michael H. Davidson acquired 5,000 shares of the business’s stock in a transaction dated Thursday, June 20th. The stock was acquired at an average price of $17.26 per share, with a total value of $86,300.00. Following the completion of the transaction, the chief executive officer now owns 204,784 shares of the company’s stock, valued at $3,534,571.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the company. Parkman Healthcare Partners LLC grew its position in shares of NewAmsterdam Pharma by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after acquiring an additional 51,726 shares during the period. Opaleye Management Inc. bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $2,964,000. Schonfeld Strategic Advisors LLC lifted its position in shares of NewAmsterdam Pharma by 12.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 64,700 shares of the company’s stock valued at $598,000 after acquiring an additional 7,400 shares during the period. Wolverine Asset Management LLC raised its holdings in NewAmsterdam Pharma by 197.2% during the fourth quarter. Wolverine Asset Management LLC now owns 8,694 shares of the company’s stock worth $97,000 after buying an additional 5,769 shares during the last quarter. Finally, Fcpm Iii Services B.V. purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $132,157,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.